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Italy during the COVID-19 pandemic
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The worldwide response to the current COVID-19
pandemic has been focused on how to prevent the
disease and to protect the high-risk patient from a
potentially lethal infection. Several consensus and
guidelines articles have been published dealing with the
cardiac patient with systemic hypertension, heart
transplant or heart failure. Very little is known about the
patients, both in the pediatric as well as in the adult age,
with congenital heart disease. The peculiar physiology of
the heart with a native, repaired or palliated congenital
heart defect deserves a specialized care. Hereby we
describe the early recommendations issued by the Italian
Society of Pediatric Cardiology and Congenital Heart
Disease and how the network of the congenital cardiac
institutions in Italy reacted to the threat of potential
wide spread of the infection among this fragile kind of
patient.
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On 11 March 2020, the worldwide outbreak of coronavi-
rus infection (COVID-19) was definitively recognized as
a pandemic disease by the WHO1 and in few weeks the
toll of sick patients rapidly expanded, with more than
1500 000 confirmed cases and 94 807 deaths as of 9 April
2020 (these data are largely underrepresenting the actual
size of infected population worldwide).
The clinical feature of the COVID-19 disease is hetero-
geneous ranging from asymptomatic patients to dramatic
acute respiratory distress syndrome with high mortality
burden among older patients or those with underlying
comorbidity. While respiratory failure was originally
deemed as the main factor leading to morbidity and
mortality, primary cardiac involvement is gradually
emerging as another important player within the clinical
spectrum of COVID-19 infection,2,3 leading to arrhyth-
mias,4 cardiac troponin-I elevation due to cytokine
storm,5 stress-induced myocardial dysfunction or even
acute myocarditis.6,7 Most importantly systemic endothe-
lial dysfunction is increasingly recognized as a key player
in developing target organ dysfunction and life-threaten-
ing thromboembolic events.
The COVID-19 crisis prompted all the major scientific
societies to release recommendations aimed at driving
the care of infected patients at high risk due to cardio-
vascular comorbidities, as well as to guide treatment and
hospital access to patients with acute cardiac illness but
without, or even unknown, COVID-19 status. Among
many others, the European Society of Cardiology (ESC)
and the AMerican College of Cardiology and American
Heart Association (ACC/AHA) provided updated posi-
tion papers concerning priority for emergency catheteri-
zation laboratory access,8,9 health workers protection8,10
and indications for urgent structural interventions.11
Resource utilization is another critical point, especially
if considering that ExtraCorporeal Mechanical Circula-
tion (ECMO) support, a potentially life-saving procedure
in profound hypoxemic patients despite invasive
mechanical ventilation,12 yielded disappointing results
in COVID-19 patients,13 nonetheless leading cardiotho-
racic surgeons enter the fray in fighting the pandemic.14,15
While attention has been focused on the patient categories
most jeopardized by the COVID-19 outbreak, like the
elderly patient with cardiac comorbidities, or the one
needing urgent coronary/structural interventions or even
those waiting for heart transplantation,16,17 only a few
articles have been dedicated to the patients with congeni-
tal heart disease, mostly on the issue of resource utilization
and decision-making about indication for invasive
Clinical practice recommendations and position paper
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procedures18,19 and planning in patients needing cardiac
surgery.20 At the beginning of March 2020, after the
coronavirus had spread out of the Chinese borders, North-
ern Italy was heavily struck by the violent pandemic
outbreak of COVID-19, claiming more than 25 000 deaths
as of 26 April. Moreover, before effective lockdown coun-
termeasures could be implemented, several people moved
out of the northern cities during the early stages, thus
potentially spreading out the infection over the whole
country. In this context, the response to the crisis was
multifaceted. Some cardiology and cardiac surgery units
(mostly those in Northern Italy) were forcibly converted to
the care of severely sick COVID-19 patients, thus waiving
any kind of emergency, urgent or elective procedures on
patients with congenital heart disease. In Lombardy,
urgent care or transplant candidates have been referred,
in a hub and spoke system decreed by the regional gov-
ernment, to a unique hospital outside the epicenter of the
COVID-19 crisis and which acted as a hub for the congen-
ital cardiac population (IRCCS Policlinico S. Donato,
Milan). Another ‘COVID-19 free’ hub was the Ospedale
Bambino Gesù, Rome, which collected patients from some
centers in Southern Italy which had been entirely devoted
to the COVID-19 emergency, and acted as a transplant-
ECMO-Ventricular Assist Device (VAD) backup institu-
tion, in a dedicated building outside the main hospital,
with intensive care facilities. All the other congenital
cardiac institutions, apart from the Monaldi Hospital in
Naples, were able to provide both an enclave for nonin-
fected patients as well as a COVID-19-dedicated section.
The safeguard of these ‘COVID-19 free’ institutions was
warranted by locally and independently drafted rules,
regulating the admission and care of the incoming patient,
and were not the result of a nationally standardized care
program. Generally, all patients had coronavirus swab tests
in safe areas before being admitted to the ward. Occasion-
ally, patients deemed at high risk for COVID-19 infection
(i.e. those coming from highly infectious areas or with
known previous contact with other infected individuals)
were put on a 14-day-long quarantine if the cardiac con-
ditions had been stable enough. Other centers shut down
any elective activity while retaining the capacity for deal-
ing with the necessity of urgent surgical treatments (neo-
natal palliative procedures or urgent repair, ECMO etc.) or
invasive cardiology procedures (Rashkind septostomy,
urgent balloon valvuloplasty etc.). Currently, we have
no information about the type and number of procedures
which have been carried out during the COVID-19 pan-
demic, but a delay in the care of out-of-hospital medical
emergency situations, as it was recently described for adult
patients, is very unlikely. This is because congenital
cardiac patients are usually tightly connected to their
referral institution and experience a relatively low rate
of unexpected cardiac emergencies. The outpatient clinic
was either completely abolished or maintained for the
most urgent and frail patients, following strong triage
protocols and nasopharyngeal swab test if available. In
summary, despite having major national hubs for congeni-
tal patients in Northern and Southern Italy, the decision
whether to limit or even close congenital cardiac activity
was made entirely on a local or regional basis, and no
specific directive was ever issued by the National
Health Ministry.
The Italian Society of Pediatric Cardiology and for Con-
genital Heart Disease recently posted recommendations
to all members, based on the evidence collected by the
major Italian congenital cardiac care institutions, together
with the currently available data in the literature, which is
the subject of the current report.
Triage and general prevention
Elective procedures should be postponed until a safe
environment can be provided in terms of access to the
hospital as well as protection toward contamination of
‘COVID-19 free’ enclaves by scrupulous preemptive virus
testing, even if early infected asymptomatic patients may
go unnoticed.21 Emergency and urgent cardiological and
surgical procedures should be carried out providing maxi-
mum operator safety.9,10,20,22 Outpatient clinics should be
limited to high-risk patients (cardiac failure, pulmonary
hypertension, transplant recipients), emphasizing ade-
quate distancing and appropriate scheduling. The pediat-
ric cardiologist in charge of the outpatient clinic is
responsible for assigning priority codes for patients sched-
uled for visit and for implementation of phone/social
network at home monitoring of less urgent cases. The
creation of a network of dedicated telemedicine equip-
ment is gaining wide acceptance as a potent tool for
monitoring and even at-distance treatment and should
be encouraged.23 Personal protective equipment should
be available as needed and as elsewhere described.9 At this
stage of knowledge, routine nasopharyngeal swabs to
diagnose infected patients before admission seem reason-
able, but the role of serology study to improve patient
streaming and reduce viral spreading is still unclear.
Neonates, infants and children with
congenital heart disease
As far as is currently known, the pediatric age seems to be
partially protected from the occurrence of the typical
respiratory distress syndrome caused by COVID-19 infec-
tion,24,25 with an overall milder clinical course.26 Less than
1% of the children who had positive swabs developed
severe signs of respiratory distress or multiorgan failure,25
in stark contrast to the 5% rate as reported for adult
patients. Nevertheless, the inherent frailty of the congeni-
tal heart patient should not be overlooked, since imbalance
between the pulmonary and the systemic circulation,
cyanosis and myocardial dysfunction are common traits
of this kind of patient, often in a combined fashion.
Pediatric patients with congenital heart disease presenting
with any kind of complicated set of symptoms (Table 1)
should be regarded as potentially COVID-19 infected.27
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Patients with shunt-dependent pulmonary circulation,
especially neonates and infants after Norwood stage I
procedure or with chronic reduction of pulmonary flow
and significant cyanosis with saturation persistently less
than 85% (mostly those with severe peripheral pulmonary
stenosis, undersized systemic-to-pulmonary shunt etc.),
should be considered as the population at the highest risk
and deserve constant monitoring. Early aggressive treat-
ment should be warranted, in the event of suspected
coronavirus infection, by a dedicated respiratory/cardio-
vascular care team in a COVID-19 prepared institution.
Mildly symptomatic or well compensated patients with a
high Qp/Qs ratio (atrial and ventricular septal defects,
atrioventricular canal defects, medium sized patent duc-
tus), while taking benefit from the overall safety settings,
should be probably considered at a reduced risk in case of
COVID-19 infection. For these patients, interventional
or surgical repair should be postponed until a safe envi-
ronment can be provided and unless there is no risk of
developing irreversible pulmonary vascular disease. For
what concerns urgent and undeferrable procedures, the
joint Society of Thoracic Surgeons/American Association
of Thoracic Surgeons/Congenital Heart Surgeons Society
(STS/AATS/CHSS) document20 makes a clear and
acceptable statement. Atrial septostomy, balloon dilata-
tion of critical pulmonary/aortic stenosis and any emer-
gent/urgent postsurgical procedure in the catheterization
laboratory should not be postponed. Stabilization, either
surgically or by catheter intervention, of patients on
prostaglandin E infusion for duct-dependent disease
is recommended.
Neonates born from COVID-19-positive mothers should
be treated as potential virus carriers, since vertical trans-
mission of the infection has not been definitively ruled out.
Indeed, despite early reports showing a very low risk of
mother-to-fetus transmission,28 IgM antibodies have been
recently found in a neonate born from an infected mother.29
Urgent surgical or interventional procedure should not be
delayed in these cases, but great care must be taken to avoid
possible contamination of the COVID-19-free enclave.
Patients with single ventricle physiology after
Glenn/Fontan procedures
This is a quite peculiar subtype of population. Interstitial
pneumonia within a central venous pressure driven
pulmonary circulation is a most worrisome condition
and the negative impact of positive pressure ventilation
on pulmonary blood flow and cardiac output (CO) in
patients with cavopulmonary connection is well known.
Moreover, the recognition of a potential hypercoagulative
state in patients affected by coronavirus infection30,31
poses a threat to patients whose pulmonary blood flow
and CO rely on as low as possible vascular resistance
values. However, there use of low molecular weight
heparin as prophylactic anticoagulation is still controver-
sial32 and patients on antiaggregation/anticoagulation
medications should not modify their therapy. It is rea-
sonable to promote enhanced security actions to avoid
infections among these patients.
Patients with dysfunction of the systemic
ventricle
It is now clear that, besides the effect of adding respira-
tory distress to a borderline compensated cardiovascular
system, the coronavirus infection has a direct impact on
cardiac myocytes by exploiting the angiotensin convert-
ing enzyme 2 to enter human cells.6,33 The clinical
presentation may vary from simple yet unnoticed tran-
sient elevation of troponin levels up to the onset of severe
systolic ventricular dysfunction with reduced ejection
fraction.34,35 Pediatric patients who are on follow-up
for an otherwise stable dilative cardiomyopathy, or any
other kind of systolic impairment of the systemic ventri-
cle, who present with fever, cough, elevated serum
troponin, NT-proBNP as well as D-dimer and inflamma-
tory biomarker elevation, should be regarded as high-risk
individuals for being under COVID-19 disease. There
are still no clues as to whether endomyocardial biopsy
should be undertaken is these patients, albeit it may be
appropriate in selected cases6 with or without previous
magnetic resonance imaging study, depending on the
institutional policy, if anti-inflammatory or any other kind
of compassionate experimental therapy is planned. Man-
agement of these patients should be the standard protocol
with inotropes, vasopressors and diuretics as usual.
The adult congenital cardiac patient
Since patients with underlying cardiovascular disease are
at higher risk of morbidity and mortality, adults with
congenital cardiac disease should be instructed on how to
minimize the risk for infection. Based on the AHA/ACC
2018 guidelines for congenital heart adults,36 any patient
with complex congenital heart disease or with NYHA
class from II to IV should be considered at high risk for
complications related to COVID-19 infection (specifi-
cally for patients in physiologic class C and D). All the
previously described threats may apply to the adult
congenital patient and special attention must be paid
to those with pulmonary hypertension and with Eisen-
menger syndrome. There is no current evidence of the
impact of the coronavirus pandemic on pulmonary hyper-
tension patients, but several national health agencies
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Table 1 Factors associated with high-risk COVID-19 infection in
patients with congenital heart disease
1. Abnormal respiratory rate (more than 50 bpm between 2 and
12 months of age; more than 40 bpm between 1 and 5 years of
age; more than 30 bpm above 5 years of age)
2. Fever persisting for more than 3–5 days
3. Neurological disorders
4. Elevation of creatine-kinase MB, decreased lymphocytes,
leucopenia and elevated procalcitonin
5. Metabolic acidosis
6. Typical radiographic presentation for interstitial pneumonia
7. Pulmonary bacterial infection
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(NHS-Pulmonary Hypertension Association UK, Center
for Disease Control, Atlanta) and pulmonary hyperten-
sion-related associations provide general guidelines on
safety and prevention with emphasis on social distancing.
Management should be undertaken as usual in every
patient with pulmonary hypertension, but it is reasonable
that inhaled nitric oxide therapy might be most beneficial
to overcome the crisis, while intravenous pulmonary
vasodilators should be used with caution due to the risk
of ventilation/perfusion mismatch and worsening cyano-
sis.37 Older patients with Fontan palliation should also be
considered at increased risk, when compared with chil-
dren, due to the progression of multiorgan dysfunction
(hepatic, renal) and age-related increase of pulmonary
vascular resistances consistent with the chronic trade-off
of the cavopulmonary circulation.38
Patients with cardiac transplant
There has been a lot of concern, at the onset of the
COVID-19 pandemic, about the impact of this viral illness
while on immunosuppressive therapy due to previous
heart transplantation. Since these patients, albeit being
former congenital cardiac patients, are being followed by
posttransplant dedicated teams, it is not in the scope of this
article to bring details among this kind of population.
Pediatric cardiac transplant receivers usually share the
same problems with the adult population and current
data may suggest a milder course of COVID-19 due to a
reduced host-inflammatory response, possibly due to the
concomitant use of immunomodulatory drugs.17,39,40
Therapeutic options and interaction with
cardiac medications
There are no specific recommendations for patients with
congenital cardiac disease for what concerns medical ther-
apy. At the beginning of the pandemic, there was some
worry about the potential harm of angiotensin-converting-
enzyme inhibitors, as these drugs may enhance virus
adhesion to the target cell surface, thus promoting the
infection. However, current guidelines as well as the
available data41 do support the continued use of vasodilator
therapy in patients with heart failure. The interplay
between the COVID-19 infection and the common medi-
cal therapies in patients with congenital heart disease is
still unclear. Children and young patients with heart
defects are known to display a high prevalence of QT
duration and ventricular repolarization abnormalities, par-
ticularly after cardiac surgery. In this setting, the prophy-
lactic use of hydroxychloroquine should be cautious.42
Steroids play an interesting role, since they have been
considered as a potential risk factor for facilitating the
infection at the very early stages of the pandemic. How-
ever, the unscathed story of transplant patients as well as
the prompt recovery induced by generous doses of steroids
and intravenous immunoglobulin, in cases with coronavi-
rus-related Kawasaki-like disease due to a diffuse systemic
vasculitis,43 clear the use of steroids as a mainstay against
this potential mid-term immune-mediated complication.
An increased risk for thrombotic complications has been
reported in Covid-19-affected patients, but we have no
clues about the potential impact of coronavirus infection
on congenital cardiac patients while on anticoagulation or
antiplatelet drugs, which should of course be continued if
indicated. Similarly, no proof to recommend the prophy-
lactic use of remdesivir in this kind of patient. The use of
ECMO has been regarded as a potential life-saving tool
and thus been advocated in the critical COVID-19
patient.14,44,45 However, a word of caution has been raised
due to the inherent problems of extracorporeal mechanical
support in septic patients and the problems facing venoar-
terial support in the setting of a dysfunctional systemic
ventricle. Moreover, the peculiar anatomy and physiology
of the heart in several kinds of congenital malformations,
both native as well as after surgery, adds further complexity
to an already difficult setting. Since the costs and avail-
ability of the resource-intensive ECMO equipment and
management are another matter of concern, ECMO of
congenital cardiac patients with overlying COVID-19
infections should be prioritized to centers with recognized
experience in congenital cardiac cardiology and surgery.
Concluding remarks
The COVID-19 pandemic has an important impact on
the health system of several nations. In Italy, the overall
mortality was very high, with the most vulnerable
patients, the older ones and those with severe comorbid-
ities, carrying the highest toll. Predicting a disaster among
the population of fragile neonates with complex congen-
ital heart disease, or the adult with a Fontan procedure,
or the one with Eisenmenger disease, was easy. On the
contrary, there was no reported death46 and the swift
institution of ‘COVID-free’ dedicated areas with congen-
ital cardiac surgery and cardiology expertise helped to
reduce the risk of the infection spreading within this
particular community. It is unclear at this stage whether
treatment of pediatric patients with COVID-19, pneu-
monia and cardiac comorbidities should include upstream
use of hydroxychloroquine or chloroquine, macrolide
antibiotics and/or protease inhibitor (such as it has been
implemented for adult patients). Clinicians must discuss
potential risks and benefits of treatment, data on out-
comes needs to be collected, the patient’s condition must
be severe and the drug cannot be in short supply.
Moreover, the number of patients with congenital heart
disease and COVID-19 infection is underrepresented,
probably due to the habit of social isolation during
periods of contagious viremia such as flu. The next
frontier will be the reprise of the ordinary care and
elective surgical and cardiological procedures for all
patients while maintaining safety barriers and constant
attention against the potential recurrence of general-
ized infection. A shared multiinstitutional plan for a
coordinated response to major crises jeopardizing
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